<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01895491</url>
  </required_header>
  <id_info>
    <org_study_id>VM206RY-VM01</org_study_id>
    <nct_id>NCT01895491</nct_id>
  </id_info>
  <brief_title>Safety Study of VM206RY in Subjects With Expression of HER2 in Breast Cancer</brief_title>
  <acronym>VM206RY</acronym>
  <official_title>An Open-Label, Uncontrolled, Single Center, Phase I Trial to Assess the Safety of VM206RY in Subjects With Expression of Her2 in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reyon Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reyon Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the safety of VM206RY in subjects with
      expression of HER2 in breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events (including serious adverse events and adverse events lead to treatment discontinuation) will be described according to severity and to their relationship with the study drug and injection procedure.</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>DLT was defined as adverse events higher than grade 3 based on NCI CTCAE version 4.0 with respect to their relationship with the study drug and injection procedure until 2 weeks after final injection. MTD was defined as the highest dose evaluated for which less than 1/3 of the participants experienced DLT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of HER2 specific antibody formation in plasma at pre and post injection using ELISA or FACS</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of HER2 specific CTL response on PBMC at pre and post injection using IFN-gamma ELISPOT</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tumor response based on the Response Evaluation Criteria in Solid Tumors (RECIST version 1.1)</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of HER2 level in plasma at pre and post injection using ELISA</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of GM-CSF level in plasma at pre and post injection using ELISA</measure>
    <time_frame>Up to be confirmed as negative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of VM206Ad in whole blood at pre and post injection using Q-PCR</measure>
    <time_frame>Up to be confirmed as negative</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>CohortⅠ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VM206DNA 6mg and VM206Ad 3*10^9VP injected into the brachial muscle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CohortⅡ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VM206DNA 12mg and VM206Ad 3*10^9VP injected into the brachial muscle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CohortⅢ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VM206DNA 24mg and VM206Ad 3*10^9VP injected into the brachial muscle</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VM206DNA</intervention_name>
    <arm_group_label>CohortⅠ</arm_group_label>
    <arm_group_label>CohortⅡ</arm_group_label>
    <arm_group_label>CohortⅢ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VM206Ad</intervention_name>
    <arm_group_label>CohortⅠ</arm_group_label>
    <arm_group_label>CohortⅡ</arm_group_label>
    <arm_group_label>CohortⅢ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women, 20 years of age

          -  Stage 3 or 4 breast cancer

          -  Unresectable breast cancer with Expression of Her2 and one of the following criteria
             including

               -  Prior use of Her2-targeted therapies(Herceptin, Tykerb, taxane and capecitabine)
                  but it was not responding, with Immunohistochemistry (IHC) 3+, or IHC 2+ and
                  FISH+, or SISH+

               -  Patients received treatment that three times continuously Different
                  chemotherapies but it was not responding, with Immunohistochemistry (IHC) 2+ and
                  FISH- or SISH-, or Immunohistochemistry (IHC) 1+

               -  Prior use of six chemotherapies(Anthracycline, Taxane, Gemcitabine, Capecitabine,
                  Vinorelbine, Cyclophosphamide) but it was not responding, with
                  Immunohistochemistry (IHC) 2+ and FISH or SISH-, or Immunohistochemistry (IHC) 1+

          -  One or more measurable(or assessable) lesion of breast or metastatic site

               -  Spiral CT: ≥ 10mm diameter

               -  general measurement methods (CT, X-ray, MRI): ≥ 20mm diameter

          -  Life expectancy 6 months

          -  Signed informed consent

        Exclusion Criteria:

          -  Prior use of breast cancer vaccine

          -  Active or history of cardiovascular diseases within the past 3 months: Active
             uncontrolled cardiac disease, including cardiomyopathy, CHF(NYHA Class III~IV), and
             unstable angina, family history of congenital long QT syndrome or QT/QTc interval
             &gt;0.45 sec or torsade de points(TdP), and history of idiopathic ventricular tachycardia
             or ventricular fibrillation, LVEF &lt; 50%

          -  Patients with coronary artery disease (myocardial infarction, angina, etc.) or a
             history of coronary artery disease

          -  Patients who is required hospitalization by severe fever or required antibiotic
             treatment by serious infection

          -  Patients who is confirmed as CNS metastases. (Only, patient with stable brain
             metastases is permit. Among the patients who have not any symptom, do not see the
             progression before registered the last 2 month)

          -  History of prior malignancies other than breast cancer within the past 5 years

          -  Patients with an existing condition or a history of autoimmune disease or
             immunodeficiency disease

          -  ECOG score ≥ 3

          -  Patients with severe dysfunction in major organs

               -  Blood: WBC &lt; 3,000/㎕; Platelet &lt; 100,000/㎕; Hematocrit &lt; 30

               -  Liver: Total bilirubin ≥ 1.5 x ULN; ALT/AST ≥ 2.5 x ULN

               -  Kidney: Creatinine ≥ 1.5 x ULN

          -  Abnormal values of anti-nuclear Ab, anti-double-stranded DNA and C3, as judged by the
             investigator

          -  History of surgical procedure, chemotherapy, Herceptin treatment, corticosteroid
             therapy, immunosuppressant therapy or radiotherapy within the past 4 weeks

          -  HIV Ag/Ab, HBs Ag, HCV Ab or HTLV-1 Ab positive

          -  Psychotropic drug misuse/abuse or alcoholism

          -  Prior use of vaccine within the past 4 weeks

          -  Cumulative dose of prior doxorubicin &gt; 360 ㎎/㎡ or epirubicin &gt; 720 ㎎/㎡

          -  Women who is pregnant or breastfeeding and don't agree to use a contraceptive during
             the study period.

          -  Patients who have participated in clinical trials enrolled in this clinical trial
             within 4 weeks before. (Only patient, who has taken survey and DNA test without
             drug-treatment, has permit.)

          -  Patients who are ineligible to participate in this study, as judged by the
             investigator.

          -  Patients who prohibit administering GM-CSF and prior use of GM-CSF within the past 4
             weeks.

          -  Patients who expect hypersensitivity to investigational product (VM206RY) or any
             component of product.

          -  Due to malignancy neoplasm, patients who require supplementary oxygen or has severe
             dyspnea at rest

          -  Patients with hypertension [inadequately controlled hypertension (systolic &gt; 180 mm Hg
             or diastolic &gt; 100 mm Hg)] or a history of hypertension
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2013</study_first_submitted>
  <study_first_submitted_qc>July 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2013</study_first_posted>
  <last_update_submitted>January 20, 2015</last_update_submitted>
  <last_update_submitted_qc>January 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

